Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Idaho Falls, ID
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Evanston, IL
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Evanston, IL
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Morton Grove, IL
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Morton Grove, IL
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Springfield, IL
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Evansville, IN
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Evansville, IN
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Indianapolis, IN
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Prairie Village, KA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Prairie Village, KA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Wichita, KA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Louisville, KY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
New Orleans, LA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Slidell, LA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Slidell, LA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Wheaton, MD
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Wheaton, MD
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Fall River, MA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Fall River, MA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Springfield, MA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Kalamazoo, MI
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Lansing, MI
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Lansing, MI
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
St. Louis, MO
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Las Vegas, NV
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Reno, NV
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Reno, NV
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Dover, NH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Dover, NH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Berlin, NJ
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Berlin, NJ
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Mercerville, NJ
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Mercerville, NJ
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Johnson City, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Johnson City, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Kingston, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Kingston, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
New York, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
North Massapequa, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
North Massapequa, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Rochester, NY
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Charlotte, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Gastonia, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Gastonia, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Hickory, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Hickory, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Statesville, NC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Statesville, NC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Cleveland, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Columbus, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Concinnati, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Concinnati, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Mayfield Village, OH
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Mayfield Village, OH
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Tulsa, OK
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Medford, OR
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Duncansville, PA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Philadelphia, PA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
West Reading, PA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
West Reading, PA
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Charleston, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Greer, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Hampton, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Hampton, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Murrells Inlet, SC
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Murrells Inlet, SC
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Memphis, TN
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Austin, TX
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Dallas, TX
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/13/2017
GSK Investigational Site
mi
from
Everett, WA
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/13/2017
GSK Investigational Site
mi
from
Everett, WA
Click here to add this to my saved trials